Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus FERABRIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus FERABRIGHT.
DEXFERRUM vs FERABRIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Iron replacement therapy: provides elemental iron for erythropoiesis, correcting iron deficiency anemia.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
Intravenous bolus of 100 mg ferric carboxymaltose (elemental iron), administered no more than 3 times per week until iron repletion is achieved.
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Terminal elimination half-life is 12-18 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Renal elimination of unchanged drug accounts for approximately 60-70% of total clearance, with biliary/fecal excretion contributing 20-30%. The remainder undergoes hepatic metabolism.
Category C
Category C
Iron Supplement
Iron Supplement